Skip to main content

Table 3 Immunological profiling leads to identification of specific cellular markers for UC and to markers signifying therapeutic responses

From: Immunological profiling of patients with ulcerative colitis leads to identification of two inflammatory conditions and CD1a as a disease marker

Leukocytes [% FoP]

UC/Non UC

TNFa-blocker/all other

Glucocorticoid/all other

Mesalazine/all other

Immunosuppressiva/all other

Δ

p value

95% CI

Δ

p value

95% CI

Δ

p value

95% CI

Δ

p value

95% CI

Δ

p value

95% CI

CD19+

−8.80

0.05

−0.1 to 17.7

−10.78

  

24.07

0.01

5.1 to 43.0

−3.99

  

25.85

0.05

−1.0 to 52.78

CD19+ CD27+ IgD+

−6.07

  

5.50

  

−13.67

0.009

−23.74 to −3.58

6.47

  

−16.27

0.006

−27.45 to −5.08

CD19+ CD27+ IgD−

10.57

  

3.47

  

18.65

0.002

7.0 to 30.27

−1.56

  

20.36

0.002

7.82 to 32.88

CD19+ CD38+

−37.10

5E−03

23.4 to 52.5

−29.82

8E−04

−45.8 to −13.2

14.75

  

−4.10

  

27.99

0.05

0.46 to 55.5

CD4+

−8.56

0.006

2.7 to 14.9

2.00

  

−2.71

  

−6.64

  

8.63

0.03

0.8 to 16.4

CD4+ CD25+

−7.16

3E−05

4.1 to 10.4

−2.20

  

−0.68

  

−2.64

  

5.53

  

CD8+

−0.19

  

−4.75

  

1.30

  

0.97

  

11.60

0.008

4.0 to 19.78

CD11b+

−6.31

0.005

2.1 to 11.2

−4.12

  

2.85

  

−2.93

  

−0.86

  

CD11b+ TSLPR+

3.73

  

−15.36

0.04

−30.26 to −0.44

23.92

0.03

2.4 to 45.3

0.08

  

23.55

  

CD11b+ CD1a+

17.73

5E−04

−27.9 to −8.3

4.10

  

−12.65

  

8.76

  

−6.59

  

CD11b+ CD80/86+

−0.97

  

−12.86

0.04

−25.3 to −0.35

0.38

  

9.17

  

3.95

  

CD14+

−0.14

  

−0.86

  

0.37

  

−0.83

  

−0.67

  

CD14+ CCR2+

15.58

  

−5.78

  

11.75

  

−1.05

  

1.59

  

CD14+ CD80/86+

−10.69

  

8.03

  

−26.71

0.03

−49.95 to −3.4

−2.07

  

−20.97

  

CD14+ TSLPR+

3.53

0.03

−8.4 to −0.5

6.74

0.03

0.8 to 12.4

1.67

  

1.79

  

3.00

  

CD14+ CD1a+

20.35

0.02

−40.8 to -4.5

6.91

  

4.38

  

6.40

  

3.76

  

CD14+ CD64+

−9.87

0.06

 

−0.14

  

−0.51

  

−0.66

  

0.50

  

CD14+ CD163+

−3.54

0.05

6.0 to 2.5

0.15

  

−2.03

  

0.00

  

−0.99

  

CD3− CD56+ 

−0.65

  

−0.58

  

1.80

  

−2.59

  

4.39

  

CD3+ CD56+

6.35

0.001

−10.3 to −2.6

−1.41

  

−4.94

  

3.22

  

−4.36

  

Factors [µg/ml]

               

TARC

1.79

  

−6.69

1E−04

32.57 to 99.45

4.25

  

−1.34

  

5.91

3E−03

23.92 to 94.34

HGF

1.41

6E−04

−21.98 to −0.62

2.02

0.001

−32.20 to −0.82

2.05

0.03

0.18 to 39.11

−0.11

  

1.63

  

TGFß1

16.76

3E−03

23.53 to 38.14

−22.13

0.01

52.94 to 30.81

−24.15

0.03

−45.31 to −29.97

−4.36

  

−26.47

0.05

−53.10 to −0.16

Periostin

−13.43

  

−21.17

  

−29.87

0.02

−53.84 to −59.07

−1.47

  

−17.06

  
  1. PBMC and serum from UC patients and Non UC patients were isolated and subjected to flow cytometric analysis. The table displays differences of mean values of frequency of immune cells in the blood and serum levels of factors. UC patients versus Non UC donors, UC patients treated with TNFa blocker, Glucocorticoid, Mesalazine and Immunesupprssiva compared to all other patients (complete data set in Additional file 1: Table S1)
  2. A two-sided t-test and a significance level = 0.05 was used to compare groups. Differences in mean values = Δ. CI confidence interval. Significantly altered values are depicted in italic numbers
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us